# Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar

> **NCT04425382** · — · COMPLETED · sponsor: **Hamad Medical Corporation** · enrollment: 400 (actual)

## Conditions studied

- Coronavirus
- COVID
- Pneumonia

## Interventions

- **DRUG:** Darunavir/Cobicistat
- **DRUG:** Lopinavir/Ritonavir

## Key facts

- **NCT ID:** NCT04425382
- **Lead sponsor:** Hamad Medical Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-01
- **Primary completion:** 2020-07-31
- **Final completion:** 2020-09-30
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2022-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04425382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04425382, "Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04425382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*